Skip to product information
1 of 1

Elabscience

SKU:PKSH033849

Recombinant Human Sialic acid-binding Ig-like lectin 15/Siglec-15/CD33L3 (C-mFC)

Recombinant Human Sialic acid-binding Ig-like lectin 15/Siglec-15/CD33L3 (C-mFC)

Regular price $200.00 USD
Regular price Sale price $200.00 USD
Sale Sold out
Shipping calculated at checkout.
Size
Introducing the Recombinant Human Sialic Acid-Binding Ig-Like Lectin 15/SIGLEC-15/CD33L3 (C-MFC), a cutting-edge product that is designed to revolutionize the field of immunology. This product is a recombinant protein that is derived from the human sialic acid-binding Ig-like lectin 15 (SIGLEC-15) gene, which is also known as CD33L3.

The Recombinant Human Sialic Acid-Binding Ig-Like Lectin 15/SIGLEC-15/CD33L3 (C-MFC) is a highly purified protein that is produced using advanced recombinant DNA technology. It is a soluble protein that is expressed in mammalian cells and is designed to bind to sialic acid residues on glycoproteins and glycolipids.

This product has a wide range of applications in the field of immunology, including the study of immune cell activation, differentiation, and migration. It can also be used in the development of novel immunotherapies for the treatment of various diseases, including cancer and autoimmune disorders.

The Recombinant Human Sialic Acid-Binding Ig-Like Lectin 15/SIGLEC-15/CD33L3 (C-MFC) is a high-quality product that is manufactured in compliance with strict quality control standards. It is available in various quantities to meet the needs of researchers and scientists in the field of immunology.

In summary, the Recombinant Human Sialic Acid-Binding Ig-Like Lectin 15/SIGLEC-15/CD33L3 (C-MFC) is a cutting-edge product that offers a wide range of applications in the field of immunology. It is a highly purified protein that is produced using advanced recombinant DNA technology and is designed to bind to sialic acid residues on glycoproteins and glycolipids. This product is a valuable tool for researchers and scientists who are working to advance the field of immunology and develop novel immunotherapies for the treatment of various diseases.
View full details